288 reports of this reaction
4.1% of all PHENYTOIN SODIUM reports
#3 most reported adverse reaction
CONVULSION is the #3 most commonly reported adverse reaction for PHENYTOIN SODIUM, manufactured by Mylan Pharmaceuticals Inc.. There are 288 FDA adverse event reports linking PHENYTOIN SODIUM to CONVULSION. This represents approximately 4.1% of all 6,984 adverse event reports for this drug.
Patients taking PHENYTOIN SODIUM who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is moderately reported among PHENYTOIN SODIUM users, representing a notable but not dominant share of adverse events.
In addition to convulsion, the following adverse reactions have been reported for PHENYTOIN SODIUM:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 288 FDA reports for PHENYTOIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 4.1% of all adverse event reports for PHENYTOIN SODIUM, making it one of the most commonly reported side effect.
If you experience convulsion while taking PHENYTOIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.